Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial

Matthias Griese, Stefano Costa, Rachel W. Linnemann, Marcus A. Mall, Edward F. McKone, Deepika Polineni, Bradley S. Quon, Felix C. Ringshausen, Jennifer L. Taylor-Cousar, Nicholas J. Withers, Samuel M. Moskowitz, Cori L. Daines

Research output: Contribution to journalLetterpeer-review

120 Scopus citations
Original languageEnglish
Pages (from-to)381-385
Number of pages5
JournalAmerican journal of respiratory and critical care medicine
Issue number3
StatePublished - Feb 1 2021

Cite this